Our approach may further benefit by combining treatments that modulate the myeloid compartment, such as low-dose irradiation (9) and colony-stimulating factor 1 receptor (CSF1R) inhibitors (52) that can drive tumor infiltration and/or polarize macrophages from an antiinflammatory M2 toward a tumoricidal M1 endotype (53). This evidence concerns the gene CSF1R and neoplasm.